BR112022004624A2 - Derivados de indol e indazol sulfonamido 4-substituído como inibidores de parg - Google Patents

Derivados de indol e indazol sulfonamido 4-substituído como inibidores de parg

Info

Publication number
BR112022004624A2
BR112022004624A2 BR112022004624A BR112022004624A BR112022004624A2 BR 112022004624 A2 BR112022004624 A2 BR 112022004624A2 BR 112022004624 A BR112022004624 A BR 112022004624A BR 112022004624 A BR112022004624 A BR 112022004624A BR 112022004624 A2 BR112022004624 A2 BR 112022004624A2
Authority
BR
Brazil
Prior art keywords
indole
substituted sulfonamido
parg
indazole derivatives
inhibitors
Prior art date
Application number
BR112022004624A
Other languages
English (en)
Inventor
Clifford Sutton James Jr
Patrick Dillon Michael
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of BR112022004624A2 publication Critical patent/BR112022004624A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

derivados de indol e indazol sulfonamido 4- substituído como inibidores de parg. a presente invenção refere-se a compostos possuindo a fórmula: ou um sal farmaceuticamente aceitável do mesmo, em que r1, r2, r3, r4, r5, r6, r7, ar, x1, x2 e o anel b possuem os significados fornecidos nesta invenção. os compostos fornecidos são inibidores úteis da poli adp-ribose glicohidrolase (parg).
BR112022004624A 2019-09-20 2020-09-18 Derivados de indol e indazol sulfonamido 4-substituído como inibidores de parg BR112022004624A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962903438P 2019-09-20 2019-09-20
PCT/US2020/051486 WO2021055744A1 (en) 2019-09-20 2020-09-18 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors

Publications (1)

Publication Number Publication Date
BR112022004624A2 true BR112022004624A2 (pt) 2022-05-31

Family

ID=72744866

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004624A BR112022004624A2 (pt) 2019-09-20 2020-09-18 Derivados de indol e indazol sulfonamido 4-substituído como inibidores de parg

Country Status (12)

Country Link
US (1) US20220389003A1 (pt)
EP (1) EP4031249A1 (pt)
JP (1) JP2022548690A (pt)
KR (1) KR20220066922A (pt)
CN (1) CN114555593A (pt)
AU (1) AU2020348489A1 (pt)
BR (1) BR112022004624A2 (pt)
CA (1) CA3147493A1 (pt)
IL (1) IL291436A (pt)
MX (1) MX2022003276A (pt)
TW (1) TW202120501A (pt)
WO (1) WO2021055744A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
TW202342458A (zh) * 2022-02-14 2023-11-01 美商雅瑞斯醫療公司 Ｐａｒｇ抑制劑
CN116693519A (zh) * 2022-03-04 2023-09-05 上海璎黎药业有限公司 一种含五元杂芳环结构化合物、其药物组合物及应用
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
TW202345809A (zh) * 2022-03-23 2023-12-01 美商愛德亞生物科學公司 作為parg抑制劑之經哌取代的吲唑化合物
WO2023208092A1 (en) * 2022-04-28 2023-11-02 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
WO2023224998A1 (en) * 2022-05-17 2023-11-23 858 Therapeutics, Inc. Inhibitors of parg
US11939335B2 (en) 2022-05-17 2024-03-26 858 Therapeutics, Inc. Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG
WO2024017306A1 (zh) * 2022-07-19 2024-01-25 苏州信诺维医药科技股份有限公司 含硫杂芳环化合物、其药物组合物及其用途
EP4311829A1 (en) 2022-07-28 2024-01-31 Nodus Oncology Limited Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
WO2024080792A1 (en) * 2022-10-13 2024-04-18 Hanmi Pharm. Co., Ltd. Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
MA41179A (fr) * 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg

Also Published As

Publication number Publication date
CN114555593A (zh) 2022-05-27
KR20220066922A (ko) 2022-05-24
IL291436A (en) 2022-05-01
US20220389003A1 (en) 2022-12-08
EP4031249A1 (en) 2022-07-27
CA3147493A1 (en) 2021-03-25
JP2022548690A (ja) 2022-11-21
TW202120501A (zh) 2021-06-01
AU2020348489A1 (en) 2022-05-05
MX2022003276A (es) 2022-04-11
WO2021055744A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
BR112022004624A2 (pt) Derivados de indol e indazol sulfonamido 4-substituído como inibidores de parg
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2007003603A (es) Metodos para preparar compuestos de indazol.
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
BRPI0517314A (pt) derivados de indol e benzimidazol
ZA202201329B (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
UA109525C2 (xx) Алкіламідна сполука і її застосування
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12019502562A1 (en) N-substituted indole derivatives
EA202191519A1 (ru) Модуляторы trex1
MX2021001565A (es) Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad).
EA202190759A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
TR201904639T4 (tr) Muskarinik M1 reseptörü pozitif allosterik modülatörler.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
EA202190718A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
CO2018002516A2 (es) Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos
AU2018326785A1 (en) Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
NZ631388A (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
MX2022002069A (es) Inhibidores de enzimas.
BR112016009811A2 (pt) derivado de carboximetil piperidina